🔗 Visit the ClinicalTrials.gov page for NCT00567359
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations. | J Thorac Oncol | 2011 | 1.34 |
| 2 | Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer. | Transl Lung Cancer Res | 2015 | 0.88 |
| 3 | How close are we to customizing chemotherapy in early non-small cell lung cancer? | Ther Adv Med Oncol | 2011 | 0.77 |